Cart
sales@molnova.com
Izencitinib
CAS No. 2051918-33-1
Izencitinib( —— )
Catalog No. M34800 CAS No. 2051918-33-1
Izencitinib (JNJ-8398) is an orally active and gut-selective JAK inhibitor with potential anti-inflammatory activity for the study of ulcerative colitis and Crohn;s disease.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 123 | Get Quote |
|
| 5MG | 187 | Get Quote |
|
| 10MG | 297 | Get Quote |
|
| 25MG | 579 | Get Quote |
|
| 50MG | 908 | Get Quote |
|
| 100MG | 1431 | Get Quote |
|
| 200MG | 1962 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameIzencitinib
-
NoteResearch use only, not for human use.
-
Brief DescriptionIzencitinib (JNJ-8398) is an orally active and gut-selective JAK inhibitor with potential anti-inflammatory activity for the study of ulcerative colitis and Crohn;s disease.
-
DescriptionIzencitinib (TD-1473) is an orally active, non-selective and gut-restricted JAK inhibitor. Izencitinib (TD-1473) can be used in the study for ulcerative colitis.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetJAK
-
RecptorJAK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2051918-33-1
-
Formula Weight402.5
-
Molecular FormulaC22H26N8
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 50 mg/mL (124.22 mM; Ultrasonic )
-
SMILESCc1cc(Nc2cc3ncccc3c(N[C@H]3C[C@@H]4CC[C@H](C3)N4CCC#N)n2)n[nH]1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Kevin S Currie, et al. Small-molecule agents for the treatment of inflammatory bowel disease. Bioorg Med Chem Lett. 2019 Aug 15;29(16):2034-2041.?
molnova catalog
related products
-
Pumecitinib
Pumecitinib is a Janus kinase (JAK) inhibitor. Pumecitinib exhibits anti-inflammatory activity.
-
CYT387
A potent and selective JAK1/JAK2 inhibitor with IC50 of 11/18 nM.
-
CHZ-868
A potent type II JAK2 inhibitor; inhibits the proliferation of SET2 JAK2 V617F cells.
